The role of carcinogen-metabolizing enzyme polymorphisms in cancer susceptibility.

[1]  J. Brockmöller,et al.  Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. , 1996, Cancer research.

[2]  F. Guengerich,et al.  Characterization of purified human recombinant cytochrome P4501A1-Ile462 and -Val462: assessment of a role for the rare allele in carcinogenesis. , 1996, Cancer research.

[3]  T. Rustan,et al.  Human N-acetylation of benzidine: role of NAT1 and NAT2. , 1996, Cancer research.

[4]  M. Yamamoto,et al.  Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. , 1996, Cancer research.

[5]  M. Ingelman-Sundberg,et al.  Nomenclature for human CYP2D6 alleles. , 1996, Pharmacogenetics.

[6]  P. Beaune,et al.  Human cytochrome P450 2E1 (CYP2E1): from genotype to phenotype. , 1996, Pharmacogenetics.

[7]  E. Perez-stable,et al.  CYP2D6 phenotype and the metabolism of nicotine and cotinine. , 1996, Pharmacogenetics.

[8]  R. Hayes,et al.  The impact of interindividual variation in NAT2 activity on benzidine urinary metabolites and urothelial DNA adducts in exposed workers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[9]  D W Nebert,et al.  P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. , 1996, Pharmacogenetics.

[10]  Harris Cc,et al.  The 1995 Walter Hubert Lecture--molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene. , 1996, British Journal of Cancer.

[11]  O. Gotoh,et al.  cDNA cloning of a murine homologue of Drosophila single-minded, its mRNA expression in mouse development, and chromosome localization. , 1996, Biochemical and biophysical research communications.

[12]  P. Dayer,et al.  The effect of tobacco on lung cancer risk depends on CYP2D6 activity. , 1996, Cancer research.

[13]  S. London,et al.  Lung cancer risk in African-Americans in relation to a race-specific CYP1A1 polymorphism. , 1995, Cancer research.

[14]  Y. Fujii‐Kuriyama,et al.  Polymorphic forms of the Ah receptor and induction of the CYP1A1 gene. , 1995, Pharmacogenetics.

[15]  J. Barrett.  Mechanisms for species differences in receptor-mediated carcinogenesis. , 1995, Mutation research.

[16]  N. Rothman,et al.  Lung cancer and CYP2D6 (the debrisoquine polymorphism): sources of heterogeneity in the proposed association. , 1995, Pharmacogenetics.

[17]  P. de Coppet,et al.  Human glutathione S-transferase M1 null genotype is associated with a high inducibility of cytochrome P450 1A1 gene transcription. , 1995, Cancer research.

[18]  P. Fernández-Salguero,et al.  The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. , 1995, Pharmacogenetics.

[19]  D. Bell,et al.  Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. , 1995, Cancer research.

[20]  D. Bell,et al.  Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. , 1995, Cancer research.

[21]  P. Beaune,et al.  CYP2D6 genotype and lung cancer risk according to histologic type and tobacco exposure. , 1995, Carcinogenesis.

[22]  V. Dolžan,et al.  Human CYP2D6 gene polymorphism in Slovene cancer patients and healthy controls. , 1995, Carcinogenesis.

[23]  K. Noda,et al.  Risk of smoking for squamous and small cell carcinomas of the lung modulated by combinations of CYP1A1 and GSTM1 gene polymorphisms in a Japanese population. , 1995, Carcinogenesis.

[24]  E. Gallagher,et al.  Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. , 1995, Pharmacogenetics.

[25]  O Pelkonen,et al.  A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. , 1995, American journal of human genetics.

[26]  K. Nakachi,et al.  Association of cigarette smoking and CYP1A1 polymorphisms with adenocarcinoma of the lung by grades of differentiation. , 1995, Carcinogenesis.

[27]  S. London,et al.  Polymorphism of glutathione S-transferase M1 and lung cancer risk among African-Americans and Caucasians in Los Angeles County, California. , 1995, Journal of the National Cancer Institute.

[28]  D. Bell,et al.  Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. , 1995, Cancer research.

[29]  M. Denison,et al.  Xenobiotic-inducible Transcription of Cytochrome P450 Genes (*) , 1995, The Journal of Biological Chemistry.

[30]  T. Nurminen,et al.  Pulmonary expression of glutathione S-transferase M3 in lung cancer patients: association with GSTM1 polymorphism, smoking, and asbestos exposure. , 1995, Cancer research.

[31]  K. Buetow,et al.  Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. , 1995, Pharmacogenetics.

[32]  G. Chenevix-Trench,et al.  Glutathione S-transferase M1 and T1 polymorphisms: susceptibility to colon cancer and age of onset. , 1995, Carcinogenesis.

[33]  P. Engstrom,et al.  Glutathione S-Transferase Activity and Glutathione S-Transferase μ Expression in Subjects with Risk for Colorectal Cancer , 1995 .

[34]  E. Bowman,et al.  Human Lung Carcinogen—DNA Adduct Levels Mediated by Genetic Polymorphisms In Vivo , 1995 .

[35]  G. Semenza,et al.  Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[36]  R. Kim,et al.  Interindividual variability of chlorzoxazone 6‐hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms , 1995, Clinical pharmacology and therapeutics.

[37]  Hayes-Davis Rb.  Genetic susceptibility and occupational cancer. , 1995 .

[38]  I. Phillips,et al.  The molecular biology of the flavin-containing monooxygenases of man. , 1995, Chemico-biological interactions.

[39]  K. McGlynn,et al.  Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[40]  E. Bresnick,et al.  Analysis of within-subject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-acetyltransferase-2 activities. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[41]  M. Costa.  Model for the epigenetic mechanism of action of nongenotoxic carcinogens. , 1995, American Journal of Clinical Nutrition.

[42]  T. Katoh,et al.  Cytochrome P4501A1 gene polymorphism and homozygous deletion of the glutathione S-transferase M1 gene in urothelial cancer patients. , 1995, Carcinogenesis.

[43]  M. Relling,et al.  Nomenclature for N-acetyltransferases. , 1995, Pharmacogenetics.

[44]  E. Vesell,et al.  Studies on interindividual variations of CYP2E1 using chlorzoxazone as an in vivo probe. , 1995, Pharmacogenetics.

[45]  E. Taioli,et al.  Functional significance of different human CYP1A1 genotypes. , 1994, Carcinogenesis.

[46]  J. Goldstein,et al.  Biochemistry and molecular biology of the human CYP2C subfamily. , 1994, Pharmacogenetics.

[47]  M A Butler,et al.  Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[48]  S. W. Lee,et al.  CYP1A2 activity as a risk factor for bladder cancer. , 1994, Journal of Korean medical science.

[49]  Y Fujii-Kuriyama,et al.  Dioxin binding activities of polymorphic forms of mouse and human arylhydrocarbon receptors. , 1994, The Journal of biological chemistry.

[50]  T. Tennenbaum,et al.  Role of oncogenes and tumor suppressor genes in multistage carcinogenesis. , 1994, The Journal of investigative dermatology.

[51]  J. Idle,et al.  Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility. , 1994, Environmental health perspectives.

[52]  E. Glover,et al.  Analysis of the four alleles of the murine aryl hydrocarbon receptor. , 1994, Molecular pharmacology.

[53]  G R Wilkinson,et al.  Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. , 1994, Molecular pharmacology.

[54]  S. Davis,et al.  Effect of fasting and obesity in humans on the 6‐hydroxylation of chlorzoxazone: A putative probe of CYP2E1 activity , 1994, Clinical pharmacology and therapeutics.

[55]  M. Oshimura,et al.  Human arylhydrocarbon receptor: functional expression and chromosomal assignment to 7p21. , 1994, Journal of biochemistry.

[56]  G. Clark,et al.  Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. , 1994, Pharmacogenetics.

[57]  H. Hiroshi,et al.  Biochemistry and molecular biology of drug-metabolizing sulfotransferase. , 1994 .

[58]  C. Hassett,et al.  The human microsomal epoxide hydrolase gene (EPHX1): complete nucleotide sequence and structural characterization. , 1994, Genomics.

[59]  R. Branch,et al.  Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity. , 1994, Carcinogenesis.

[60]  A. Rannug,et al.  Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer types. , 1994, Carcinogenesis.

[61]  S. R. Babu,et al.  Human liver glucuronidation of benzidine. , 1994, Carcinogenesis.

[62]  J. Brockmöller,et al.  Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: a case-control study. , 1994, Cancer research.

[63]  K. Kawajiri,et al.  Different regulation and expression of the human CYP2E1 gene due to the RsaI polymorphism in the 5'-flanking region. , 1994, Journal of biochemistry.

[64]  W. Schulz,et al.  Loss of heterozygosity at the NAD(P)H: quinone oxidoreductase locus associated with increased resistance against mitomycin C in a human bladder carcinoma cell line. , 1994, Biological chemistry Hoppe-Seyler.

[65]  T. Kamataki,et al.  Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[66]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[67]  R. Kim,et al.  Relationship in healthy subjects between CYP2E1 genetic polymorphisms and the 6-hydroxylation of chlorzoxazone: a putative measure of CYP2E1 activity. , 1994, Pharmacogenetics.

[68]  B. Tang,et al.  Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements. , 1994, Pharmacogenetics.

[69]  U. Fuhr,et al.  Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. , 1994, Pharmacogenetics.

[70]  T. Nurminen,et al.  Combined effect of CYP1A1 inducibility and GSTM1 polymorphism on histological type of lung cancer. , 1994, Carcinogenesis.

[71]  C. Jefcoate,et al.  Dual regulation of cytochrome P450EF expression via the aryl hydrocarbon receptor and protein stabilization in C3H/10T1/2 cells. , 1994, Molecular pharmacology.

[72]  C. Jefcoate,et al.  Mouse cytochrome P-450EF, representative of a new 1B subfamily of cytochrome P-450s. Cloning, sequence determination, and tissue expression. , 1994, The Journal of biological chemistry.

[73]  Steven R. Tannenbaum,et al.  Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens , 1994, Nature.

[74]  D. Bernstein,et al.  Ethnic distribution of the glutathione transferase Mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility. , 1994, Carcinogenesis.

[75]  O. Gotoh,et al.  Interindividual difference in expression of human Ah receptor and related P450 genes. , 1994, Carcinogenesis.

[76]  D. Thomas,et al.  Methodological issues in the interpretation of studies of the CYP2D6 genotype in relation to lung cancer risk. , 1994, Pharmacogenetics.

[77]  A. Brøgger,et al.  Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls. , 1994, Pharmacogenetics.

[78]  R. Kanamaru,et al.  Restriction fragment length polymorphism of the human CYP2E1 (cytochrome P450IIE1) gene and susceptibility to lung cancer: possible relevance to low smoking exposure. , 1994, Pharmacogenetics.

[79]  J R Cashman,et al.  The mammalian flavin-containing monooxygenases: molecular characterization and regulation of expression. , 1994, Toxicology and applied pharmacology.

[80]  D. Nebert,et al.  1462V mutation in the human CYP1A1 gene: lack of correlation with either the Msp I 1.9 kb (M2) allele or CYP1A1 inducibility in a three-generation family of east Mediterranean descent. , 1994, Pharmacogenetics.

[81]  J. Idle,et al.  Poor metabolisers of nicotine and CYP2D6 polymorphism , 1994, The Lancet.

[82]  J. Miners,et al.  The glucuronidation of hydroxylated metabolites of benzo[a]pyrene and 2-acetylaminofluorene by cDNA-expressed human UDP-glucuronosyltransferases. , 1993, Carcinogenesis.

[83]  S. Anttila,et al.  Immunohistochemical localization of glutathione S-transferases in human lung. , 1993, Cancer research.

[84]  A. Guillouzo,et al.  Both cytochromes P450 2E1 and 1A1 are involved in the metabolism of chlorzoxazone. , 1993, Chemical research in toxicology.

[85]  H. Swanson,et al.  The AH-receptor: genetics, structure and function. , 1993, Pharmacogenetics.

[86]  E. Taioli,et al.  Relationship between genotype and function of the human CYP1A1 gene. , 1993, Journal of toxicology and environmental health.

[87]  N K Spurr,et al.  Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. , 1993, Carcinogenesis.

[88]  W. Kalow.  Pharmacogenetics: Its biologic roots and the medical challenge , 1993, Clinical pharmacology and therapeutics.

[89]  W. Pearson,et al.  Homozygous deletion of gene for glutathione S-transferase M1 in bladder cancer. , 1993, BMJ.

[90]  W. Weber,et al.  Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltransferase (NAT1) of peripheral blood. , 1993, Pharmacogenetics.

[91]  E. Bowman,et al.  Polycyclic aromatic hydrocarbon-DNA adducts in human lung and cancer susceptibility genes. , 1993, Cancer research.

[92]  Jack A. Taylor,et al.  Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. , 1993, Journal of the National Cancer Institute.

[93]  H Vainio,et al.  The GSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung. , 1993, Carcinogenesis.

[94]  K. Nakachi,et al.  Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. , 1993, Cancer research.

[95]  W. Pearson,et al.  Identification of class-mu glutathione transferase genes GSTM1-GSTM5 on human chromosome 1p13. , 1993, American journal of human genetics.

[96]  D. Adler,et al.  Human and rabbit paraoxonases: purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification. , 1993, Chemico-biological interactions.

[97]  A. Lafuente,et al.  Enhanced glutathione S-transferase activity and glutathione content in human bladder cancer. Followup study: influence of smoking. , 1993, The Journal of urology.

[98]  D. Hémon,et al.  Fundamentals of case-control studies. , 1993, Pharmacogenetics.

[99]  N. Weiss,et al.  The glutathione S-transferase mu polymorphism as a marker for susceptibility to lung carcinoma. , 1993, Cancer research.

[100]  B. Tang,et al.  The use of caffeine for enzyme assays: A critical appraisal , 1993, Clinical pharmacology and therapeutics.

[101]  R. Hayes,et al.  N-acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. , 1993, Carcinogenesis.

[102]  T. Iyanagi,et al.  Glucuronidation of carcinogen metabolites by complementary DNA-expressed uridine 5'-diphosphate glucuronosyltransferases. , 1993, Cancer research.

[103]  K. Kinzler,et al.  The multistep nature of cancer. , 1993, Trends in genetics : TIG.

[104]  D. Grant,et al.  Role of polymorphic and monomorphic human arylamine N-acetyltransferases in determining sulfamethoxazole metabolism. , 1993, Biochemical pharmacology.

[105]  J. Brockmöller,et al.  Genotype and Phenotype of Glutathione S-Transferase Class µ Isoenzymes µ and ψ in Lung Cancer Patients and Controls , 1993 .

[106]  M. Waters,et al.  The genetic toxicology of putative nongenotoxic carcinogens. , 1993, Mutation research.

[107]  W. Weber,et al.  Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. , 1993, Archives of biochemistry and biophysics.

[108]  S. Anttila,et al.  PCR-based CYP2D6 genotyping for Finnish lung cancer patients. , 1993, Pharmacogenetics.

[109]  K. Nakachi,et al.  The CYP1A1 gene and cancer susceptibility. , 1993, Critical reviews in oncology/hematology.

[110]  D. Grant.  Molecular genetics of the N-acetyltransferases. , 1993, Pharmacogenetics.

[111]  A. Lafuente,et al.  Human glutathione S-transferase mu (GST mu) deficiency as a marker for the susceptibility to bladder and larynx cancer among smokers. , 1993, Cancer letters.

[112]  S. Yuspa,et al.  Critical Aspects of Initiation, Promotion, and Progression in Multistage Epidermal Carcinogenesis , 1993, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[113]  S. Anttila,et al.  Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer. , 1992, Pharmacogenetics.

[114]  M A Butler,et al.  Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis. , 1992, Environmental health perspectives.

[115]  E. Bowman,et al.  Polycyclic aromatic hydrocarbon-DNA adducts and the CYP1A1 restriction fragment length polymorphism. , 1992, Environmental health perspectives.

[116]  G. Talaska,et al.  The human glutathione S-transferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer. , 1992, Environmental health perspectives.

[117]  R. Kanamaru,et al.  Human cytochrome P450IIE1 gene: DraI polymorphism and susceptibility to cancer. , 1992, The Tohoku journal of experimental medicine.

[118]  C. Bradfield,et al.  A brief review of the Ah locus. , 1992, The Tohoku journal of experimental medicine.

[119]  O Pelkonen,et al.  Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. , 1992, Pharmacogenetics.

[120]  S. Anttila,et al.  Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. , 1992, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[121]  K. Kawajiri,et al.  High Susceptibility to Lung Cancer Analyzed in Terms of Combined Genotypes of P450IA1 and Mu‐class Glutathione S‐Transferase Genes , 1992, Japanese journal of cancer research : Gann.

[122]  R. Branch,et al.  The ability to 4-hydroxylate debrisoquine is related to recurrence of bladder cancer. , 1992, Pharmacogenetics.

[123]  R. Hayes,et al.  Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. , 1992, Pharmacogenetics.

[124]  C. Smith,et al.  Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. , 1992, Carcinogenesis.

[125]  O. Hankinson,et al.  Identification of the Ah Receptor Nuclear Translocator Protein (Arnt) as a Component of the DNA Binding Form of the Ah Receptor , 1992, Science.

[126]  J. Idle,et al.  Comparison of a novel thin-layer chromatographic-fluorescence detection method with a spectrofluorometric method for the determination of 7-hydroxycoumarin in human urine. , 1992, Journal of chromatography.

[127]  W. Pearson,et al.  Nomenclature for human glutathione transferases. , 1992, The Biochemical journal.

[128]  K. Danenberg,et al.  NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. , 1992, Cancer research.

[129]  Y. Fujii‐Kuriyama,et al.  P450 and Human Cancer , 1991, Japanese journal of cancer research : Gann.

[130]  B. Tang,et al.  Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities , 1991, Clinical pharmacology and therapeutics.

[131]  D. Nebert,et al.  Human AH locus polymorphism and cancer: inducibility of CYP1A1 and other genes by combustion products and dioxin. , 1991, Pharmacogenetics.

[132]  H. Kikuchi,et al.  MspI polymorphism of the human CYP2E gene. , 1991, Nucleic acids research.

[133]  K. Nakachi,et al.  Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. , 1991, Cancer research.

[134]  A. Brøgger,et al.  Human CYP1A1 (cytochrome P(1)450) gene: lack of association between the Msp I restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. , 1991, Pharmacogenetics.

[135]  K. Nakachi,et al.  Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. , 1991, Journal of biochemistry.

[136]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[137]  F. Gonzalez,et al.  A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. , 1991, Carcinogenesis.

[138]  T. Kamataki,et al.  Two common RFLPs of the human CYP2E gene. , 1991, Nucleic acids research.

[139]  J. Dalphin,et al.  Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancer. , 1991, British journal of clinical pharmacology.

[140]  W. Halperin,et al.  Excess number of bladder cancers in workers exposed to ortho-toluidine and aniline. , 1991, Journal of the National Cancer Institute.

[141]  D. Nebert,et al.  Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP. , 1991, American journal of human genetics.

[142]  R. Kanamaru,et al.  Association between Restriction Fragment Length Polymorphism of the Human Cytochrome P450IIE1 Gene and Susceptibility to Lung Cancer , 1991, Japanese journal of cancer research : Gann.

[143]  F. Guengerich,et al.  Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. , 1991, Chemical research in toxicology.

[144]  M. Boyd,et al.  Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. , 1990, Journal of the National Cancer Institute.

[145]  F. Kadlubar,et al.  Aromatic amine acetyltransferase as a marker for colorectal cancer: Environmental and demographic associations , 1990, International journal of cancer.

[146]  T. Aoyama,et al.  Five of 12 forms of vaccinia virus-expressed human hepatic cytochrome P450 metabolically activate aflatoxin B1. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[147]  K. Nakachi,et al.  Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P45 0IA1 gene , 1990, FEBS letters.

[148]  D. Nebert,et al.  Evolution of the P450 gene superfamily and regulation of the murine Cyp1a1 gene. , 1990, Biochemical Society transactions.

[149]  R. Hayes,et al.  Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype. , 1989, Cancer research.

[150]  W. Pearson,et al.  Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[151]  F. Guengerich.  Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. , 1988, Cancer research.

[152]  O. Mcbride,et al.  A Taq I polymorphism in the human P450IIE1 gene on chromosome 10 (CYP2E). , 1987, Nucleic acids research.

[153]  R. Branch,et al.  Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. , 1987, Cancer research.

[154]  J. Groopman,et al.  Mechanism of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) and related 1,2-dithiol-3-thiones and 1,2-dithiol-3-ones. , 1987, Cancer research.

[155]  F. Gonzalez,et al.  Stabilization of cytochrome P450j messenger ribonucleic acid in the diabetic rat. , 1987, Molecular endocrinology.

[156]  Ş. Şardaş,et al.  N-Acetyltransferase Phenotype of Patients with Bladder Cancer , 1986, Human toxicology.

[157]  D. Nebert,et al.  Tissue-specific expression of the mouse dioxin-inducible P(1)450 and P(3)450 genes: differential transcriptional activation and mRNA stability in liver and extrahepatic tissues , 1986, Molecular and cellular biology.

[158]  R. Pero,et al.  A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer. , 1986, Carcinogenesis.

[159]  R. Pero,et al.  Hereditary interindividual differences in the glutathione transferase activity towards trans-stilbene oxide in resting human mononuclear leukocytes are due to a particular isozyme(s). , 1985, Carcinogenesis.

[160]  M. Hetzel,et al.  Metabolic oxidation phenotypes as markers for susceptibility to lung cancer , 1984, Nature.

[161]  D. Grant,et al.  A simple test for acetylator phenotype using caffeine. , 1984, British journal of clinical pharmacology.

[162]  D. Evans,et al.  The association of the slow acetylator phenotype with bladder cancer. , 1983, Journal of medical genetics.

[163]  N P Wray,et al.  Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes. , 1982, Cancer research.

[164]  R. Glashan,et al.  ROLE OF N-ACETYLTRANSFERASE PHENOTYPES IN BLADDER CARCINOGENESIS: A PHARMACOGENETIC EPIDEMIOLOGICAL APPROACH TO BLADDER CANCER , 1982, The Lancet.

[165]  K. Steenland,et al.  Seasonal variation of aryl hydrocarbon hydroxylase activity in human lymphocytes. , 1981, Cancer research.

[166]  B. Paigen,et al.  Induction, inhibition, and some enzymological properties of aryl hydrocarbon hydroxylase in fresh mitogen-activated human lymphocytes. , 1979, Cancer research.

[167]  H. Wolf,et al.  N-Acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark , 1979, Environmental health perspectives.

[168]  K. Steenland,et al.  Aryl hydrocarbon hydroxylase inducibility is not altered in bladder cancer patients or their progeny , 1979, International journal of cancer.

[169]  K. Steenland,et al.  Aryl hydrocarbon hydroxylase in persons with lung or laryngeal cancer , 1978, International journal of cancer.

[170]  P. Kitzing,et al.  ARYL HYDROCARBON HYDROXYLASE INDUCIBILITY AND CARCINOMA OF ORAL CAVITY , 1978, The Lancet.

[171]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[172]  B. Paigen,et al.  Factors influencing the measurement and the reproducibility of aryl hydrocarbon hydroxylase activity in culutred human lymphocytes. , 1977, Journal of the National Cancer Institute.

[173]  I. Bross,et al.  Distribution of aryl hydrocarbon hydroxylase inducibility in cultured human lymphocytes. , 1977, Cancer research.

[174]  P. Kitzing,et al.  ARYL HYDROCARBON HYDROXYLASE INDUCIBILITY AND LARYNGEAL CARCINOMAS , 1976, The Lancet.

[175]  C R Shaw,et al.  Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. , 1973, The New England journal of medicine.

[176]  J. Groopman,et al.  Molecular biomarkers for aflatoxins and their application to human liver cancer. , 1995, Pharmacogenetics.

[177]  K. Kawajiri,et al.  Genetic polymorphisms of drug-metabolizing enzymes and lung cancer susceptibility. , 1995, Pharmacogenetics.

[178]  J. Ritter,et al.  Gene structure at the human UGT1 locus creates diversity in isozyme structure, substrate specificity, and regulation. , 1995, Progress in nucleic acid research and molecular biology.

[179]  K. Noda,et al.  Distribution of GSTM1 null genotype in relation to gender, age and smoking status in Japanese lung cancer patients. , 1995, Pharmacogenetics.

[180]  Li Fp.  Translational research on hereditary colon, breast, and ovarian cancers. , 1995 .

[181]  C. Michejda,et al.  Carcinogen activation by sulfate conjugate formation. , 1994, Advances in pharmacology.

[182]  J. Idle,et al.  Pharmacogenetic Phenotyping and Genotyping , 1994, Clinical pharmacokinetics.

[183]  T. Xie,et al.  NAD(P)H:quinone oxidoreductase1 (DT-diaphorase): expression, regulation, and role in cancer. , 1994, Oncology research.

[184]  Y. Fujii‐Kuriyama,et al.  Ah receptor: a novel ligand-activated transcription factor. , 1994, Experimental and clinical immunogenetics.

[185]  D. Currie,et al.  Racial differences in restriction fragment length polymorphisms and messenger RNA inducibility of the human CYP1A1 gene. , 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[186]  D. Adler,et al.  The molecular basis of the human serum paraoxonase activity polymorphism , 1993, Nature Genetics.

[187]  R. Branch,et al.  Bladder cancer recurrence and its association with cytochrome P-450IID6 activity. , 1992, Progress in clinical and biological research.

[188]  D. Eaton,et al.  Potent inhibition of aflatoxin-induced hepatic tumorigenesis by the monofunctional enzyme inducer 1,2-dithiole-3-thione. , 1992, Carcinogenesis.

[189]  Lang Np,et al.  Aromatic and heterocyclic amine metabolism and phenotyping in humans. , 1991 .

[190]  Y. Horsmans,et al.  Is there a link between debrisoquine oxidation phenotype and lung cancer susceptibility? , 1991, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[191]  A. Llerena,et al.  Polymorphic oxidation of debrisoquine in lung cancer patients. , 1991, European journal of cancer.

[192]  F. Gonzalez,et al.  Activation of promutagens by human cDNA-expressed cytochrome P450s. , 1990, Progress in clinical and biological research.

[193]  K. Nakachi,et al.  Individual differences in lung cancer susceptibility in relation to polymorphisms of P-450IA1 gene and cigarette dose. , 1990, Princess Takamatsu symposia.

[194]  B. Ketterer,et al.  The role of glutathione and glutathione transferases in chemical carcinogenesis. , 1990, Critical reviews in biochemistry and molecular biology.

[195]  D. Nebert,et al.  Regulation of the mammalian cytochrome P1-450 (CYP1A1) gene. , 1989, The International journal of biochemistry.

[196]  F. Guengerich.  Cytochromes P-450. , 1988, Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology.

[197]  I. Roots,et al.  Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk. , 1988, Klinische Wochenschrift.

[198]  M. Eichelbaum.  Polymorphic oxidation of debrisoquine and sparteine. , 1986, Progress in clinical and biological research.

[199]  J. Idle,et al.  Polymorphisms of oxidation at carbon centers of drugs and their clinical significance. , 1979, Drug metabolism reviews.